Anson Funds Management LP Cel Sci Corp Transaction History

Anson Funds Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$0.83 - $4.16 $279,295 - $1.4 Million	-336,500 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$0.92 - $3.5 $309,580 - $1.18 Million	336,500 New	336,500 $310,000
Q1 2018 May 15, 2018	SELL	$1.38 - $2.33 $363,158 - $613,158	-263,158 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$1.63 - $2.0 $428,947 - $526,316	263,158	263,158 $423,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Anson Funds Management LP, based on Form 13F filings with the SEC.

Stay updated on Anson Funds Management LP with notifications on news.